Selinexor 100 mg
KCP-330-027
Phase 2 small_molecule completed
Quick answer
Selinexor 100 mg for Non-Small Cell Lung Carcinoma (NSCLC) is a Phase 2 program (small_molecule) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Karyopharm Therapeutics
- Indication
- Non-Small Cell Lung Carcinoma (NSCLC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed